FDA Clearance Tracker · P250033-S002
NEXUS Aortic Arch Stent Graft System
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 24, 2026
Approved
Time to decision
85 days
Received Apr 30, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P250033-S002
- Device name
- NEXUS Aortic Arch Stent Graft System
- Applicant
- Endospan , Ltd.
- Applicant location
- Alta, WY
- Received
- Apr 30, 2026
- Decided
- Jul 24, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P250033
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250033.
Source documents
Other decisions for Endospan , Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- NEXUS Aortic Arch Stent Graft SystemBreakthroughPMA
P250033 · Decided Apr 2, 2026 · 223 days after receipt
Device type: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions (SDZ) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.